Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This feels like September. Shareholders got were hurt when HGEN did a reverse split and also a dilution. It meant you could buy shares sub-$8. It was a steal. The current sub-$20 stock price is also a steal. Shareholders were hurt again and new buyers are the beneficiaries. Thankfully, no one will care when an EUA is granted in 2 weeks.
Start manufacturing??!!! By the time they get revenue from that HGEN will be at $8.
Month 4...4 shots...phase 4...4 EUA approvals
Has CytoDyn released data to figure out total mortality in treatment vs placebo in the whole trial? I bet the treatment arm had a higher mortality percentage.
critical group and a severe group which are separate
If the trial was only the 62 patients, then it would be more impressive. Because that would be one for one. The current trial is one for six. If randomness can make Mondays seem different than Tuesdays, then randomness can have the same effect on a 16% slice of critical patients.
Looking at the entire population of critical patients as a whole is, by definition, not slicing it up.
https://biopharmajournal.com/2021/04/01/humanigen-inc-nasdaqhgen-announce-encouraging-phase-3-lenzilumab-study-results-in-hospitalized-covid-19-patients/
Mayo Clinic’s Molecular Medicine Department Head Andrew Badley said that they are pleased to have participated in the lenzilumab investigation from the initial stages of the COVID-19 development program, and they are delighted with the results. Badley said that if the FDA authorizes lenzilumab for emergency use and based on the company’s clinical study experience, it will be considered as part of the treatment armamentarium for newly hospitalized COVID-19 patients.
they still haven't submitted the CD16 protocol.
But critical patients are only 62 patients. Severe could be divided up into subgroups with bright line distinctions like high flow oxygen and low flow. When you have a trial of 394 patients and look at these secondary endpoints for subgroups, pure chance will make some of the groups look good. Not one person said it was going to work for critical and not severe. The FDA is not going to accept a 16% slice further diced to 14 days. 0% chance. That is not how they operate.
This isn't a good analogy because Monday is no different that Tuesday other than what we name it.
"only publicizing a 16% slice of the trial" when they're actually reporting on 100% of the critical patients?
I love how CYDY folks are saying the HGEN trial is sliced and diced. It is obviously true about CYDY's trial since they are only publicizing a 16% slice of the trial. HGEN's trial has 54% efficacy on 100% of the trial. No slicing. No dicing. Saying it is sliced and diced is the playground equivalent saying, "I know you are but what am I?".
Wrong again...
Slice & Diced
Manipulated
Skewed
Cherry Picked
Mediocre Data... Plus Dilution
Link please on when the FDA said CD12 did not justify an EUA
your claim of Lenzil's numbers are false.
after they claim to meet endpoints on a diced up manipulated trial.
hows the condeetional EUA coming? Been a while now.
You will see the higher price for CYDY next week. I am regret sold some Yesterday!
And wouldn't 'ya know, April 1st, we closed at 3.19!!
NP has completely ignored Incelldx since the patent was filed
No bueno. I guess HGEN's lenzilumab is the best of the anti-GM-CSF drugs for Covid. Lenzilumab's trial showed 54% efficacy. It is guaranteed an EUA within a couple of weeks yet its stock is 20% below where it was a month ago. It dropped 2 days ago because they diluted 5 million shares to pay for manufacturing.
https://www.rheumatologyadvisor.com/home/general-rheumatology/mavrilimumab-outcomes-patients-with-severe-covid19-pneumonia-hyperinflammation/
It's nice that the trade journals are writing articles covering trial news positively. All are saying the trial was a success. None are writing any concerns. Main stream media members who are researching lenzilumab will be more confident to write positively about lenz after reading the trade journal articles.
For those starting their due diligence, the below links explain how GM-CSF is the cytokine responsible for the cytokine storm, severe Covid and death. HGEN's drug, lenzilumab, is a GM-CSF inhibitor.
https://www.bbc.com/news/health-56352128
https://www.dailymail.co.uk/news/article-9346955/Blood-test-spot-Covid-patients-high-risk-dying.html
https://immunology.sciencemag.org/content/6/57/eabg9873
according to Dr Harish S and Dr Lalezari our company asked for it but at the time FDA didn't think it is needed.
you just look foolish.
CytoDyn stock is truly proving its resiliency again. It should be called CatoDyn because it clearly has 9 lives.
The company doing an offering before EUA looks sketchy
Nice "melt up" here during "power hour" like the old days.
T-trades are used to make large purchases and sales throughout the day without moving the stock price. Hedge funds use them to cover their short positions. They drop the stock price early, and then trade on the weighted average all day.
Who wants to predict how large today's T trade will be? I'm thinking it'll be just a tad lower than yesterday. 1,050,000 shares.
No placebo mentioned in pr extension. Just additional 2 doses, for total of 4 over 28 weeks. Hmmm.
I have a feeling we might see a nice melt up during power hour.
I have a feeling that anyone who is still invested in CYDY will never accept that leronlimab might not be the greatest drug ever. I can imagine people 30 years from now telling their grandchildren that this drug they were invested in was the greatest ever but it was sabotaged by FDA/NIH/BigPharma. There's one born every minute.
It’s why FDA would not let them do 4 doses in the first place. They knew it would work.
wonder if now they will just grant EUA because they know what the extra doses results will show.
I have a feeling we might see a nice melt up during power hour.
Look at Scooter getting all Bullish...
Almost makes me want to turn into a Bear lol!
Oooooo lookey- new PR swill NP is serving up today.
4 doses on 14 days in a 28 day outcome clinical trial.
I’d like to wake up to a press release that somebody in management has acquired a bunch of shares
Dale Chappell has sold zero shares. He doesn't care about pumping the stock price because this is not a pump and dump stock. It is in his self interests to raise funds in a manner that hurts the stock price in the present but doesn't hurt the future. That is why HGEN is in great financial shape. Now HGEN has a war chest to make lenzilumab for the world.
So people have thrown out $5,000 and $10,000 as potential selling prices. Has Durrant or Chappell ever said for how much they might sell lenz? How much does it cost to produce? Leronlimab costs $40 to produce either a dose or vial which is 2 doses. I'm trying to figure out how much in potential sales would result from $200 million in manufacturing?
The MSM will cover lenz when it gets an EUA. They don't like taking chances on things they don't understand. And the STAT news article is enough to make them extra cautious.